Brief: BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration

Matinas BioPharma Holdings

11/04/2022 12:03

April 11 (Reuters) - BIONTECH SE  22UAy.DE :
    * BIONTECH AND MATINAS BIOPHARMA ANNOUNCE EXCLUSIVE RESEARCH
COLLABORATION TO EVALUATE NOVEL DELIVERY TECHNOLOGY FOR
MRNA-BASED VACCINES
    * ANNOUNCED TODAY THAT THEY HAVE ENTERED INTO AN EXCLUSIVE
RESEARCH COLLABORATION TO EVALUATE COMBINATION OF MRNA FORMATS
AND MATINAS' PROPRIETARY LNC PLATFORM TECHNOLOGY
    * PARTIES WILL CLOSELY COLLABORATE ON FORMULATION,
OPTIMIZATION,
AND IN VITRO TESTING
    * UNDER TERMS OF AGREEMENT, MATINAS WILL RECEIVE AN UPFRONT
ACCESS
FEE TO WORK EXCLUSIVELY WITH BIONTECH, AS WELL AS ADDITIONAL
RESEARCH FUNDING FROM BIONTECH
    * PARTIES HAVE ALSO COMMENCED DISCUSSIONS ON A LICENSE
AGREEMENT
FOR MATINAS' LNC PLATFORM TECHNOLOGY

Source text for Eikon:  ID:nGNE6M7Zgw 
Further company coverage:  22UAy.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))